Cara Therapeutics Inc (NASDAQ: CARA) has experienced a rise in its stock price by 7.08 compared to its previous closing price of 0.27. However, the company has seen a fall of -2.56% in its stock price over the last five trading days. benzinga.com reported 2024-06-13 that Shares of Cara Therapeutics Inc CARA tanked in early trading on Thursday, with the Dow shedding more than 100 points.
Is It Worth Investing in Cara Therapeutics Inc (NASDAQ: CARA) Right Now?
Company’s 36-month beta value is 0.72.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CARA is 45.76M, and currently, short sellers hold a 2.43% ratio of that floaft. The average trading volume of CARA on September 19, 2024 was 777.93K shares.
CARA’s Market Performance
CARA’s stock has seen a -2.56% decrease for the week, with a -11.65% drop in the past month and a 17.89% gain in the past quarter. The volatility ratio for the week is 9.01%, and the volatility levels for the past 30 days are at 7.87% for Cara Therapeutics Inc The simple moving average for the past 20 days is -10.85% for CARA’s stock, with a -53.69% simple moving average for the past 200 days.
Analysts’ Opinion of CARA
Many brokerage firms have already submitted their reports for CARA stocks, with Stifel repeating the rating for CARA by listing it as a “Hold.” The predicted price for CARA in the upcoming period, according to Stifel is $1 based on the research report published on June 13, 2024 of the current year 2024.
CARA Trading at -14.87% from the 50-Day Moving Average
After a stumble in the market that brought CARA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.62% of loss for the given period.
Volatility was left at 7.87%, however, over the last 30 days, the volatility rate increased by 9.01%, as shares sank -15.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.21% upper at present.
During the last 5 trading sessions, CARA fell by -2.56%, which changed the moving average for the period of 200-days by -70.42% in comparison to the 20-day moving average, which settled at $0.3182. In addition, Cara Therapeutics Inc saw -61.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CARA starting from Posner Christopher, who sale 4,149 shares at the price of $0.35 back on Aug 01 ’24. After this action, Posner Christopher now owns 172,436 shares of Cara Therapeutics Inc, valued at $1,452 using the latest closing price.
Posner Christopher, the PRESIDENT AND CEO of Cara Therapeutics Inc, sale 3,936 shares at $0.75 during a trade that took place back on May 02 ’24, which means that Posner Christopher is holding 176,585 shares at $2,952 based on the most recent closing price.
Stock Fundamentals for CARA
Current profitability levels for the company are sitting at:
- -9.47 for the present operating margin
- 0.73 for the gross margin
The net margin for Cara Therapeutics Inc stands at -10.1. The total capital return value is set at -1.78. Equity return is now at value -184.32, with -107.38 for asset returns.
Based on Cara Therapeutics Inc (CARA), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at -2.01. The debt to equity ratio resting at 3.44. The interest coverage ratio of the stock is -23.16.
Currently, EBITDA for the company is -121.24 million with net debt to EBITDA at 0.02. When we switch over and look at the enterprise to sales, we see a ratio of 1.24. The receivables turnover for the company is 6.04for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.59.
Conclusion
In a nutshell, Cara Therapeutics Inc (CARA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
